Year: 2026
Type: article
Abstract: Skin fibrosis is characterized by excessive deposition of extracellular matrix driven by activated fibroblasts, leading to varying degrees of patient discomfort, deformity, disability, and even death. In vitro studies using mouse primary skin fibroblasts (PSFs) and patient-derived primary keloid fibroblasts (KFs) demonstrated that toddalolactone (Tod) significantly inhibited fibroblast proliferation, migration, and activation and suppressed the TGF-β1/Smad and TGF-β1/non-Smad pathways in these cells. In a bleomycin (BLM)-induced mouse model of skin fibrosis, Tod treatment significantly reduced dermal thickness and collagen deposition in mouse skin, decreased skin hydroxyproline content, and inhibited fibroblast activation as well as the TGF-β1/Smad and TGF-β1/non-Smad pathways in vivo. In a keloid xenograft mouse model, Tod treatment significantly reduced the relative weight of keloids in mice. Histopathological analysis revealed that Tod alleviated the degree of keloid fibrosis and collagen aggregation while inhibiting fibroblast activation in keloid tissue. Furthermore, molecular docking identified monoamine oxidase A (MAOA) as a potential target of Tod. Cellular thermal shift assays and MAOA knockdown using siRNA in PSFs and KFs demonstrated that Tod inhibits the TGF-β1 pathway and suppresses fibroblast activation by inhibiting MAOA. Collectively, the findings reveal that Tod regulates the TGF-β1/Smad and TGF-β1/non-Smad pathways through inhibiting MAOA, thereby affecting skin fibroblast activation and alleviating skin fibrosis.
Source: PLoS ONE
Institutions: Tianjin University, Nankai University
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
Awards: G2843885270, G3706795958
OpenAlex ID: W7234323935
